Clinical Trial Update: Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease [Phase 3]

View source ↗

Summary

Sanofi is conducting a Phase 3 trial to evaluate a single-dose, 21-valent pneumococcal conjugate vaccine in children and adolescents with sickle cell disease; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• 21-valent pneumococcal conjugate vaccine (Pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi | Conditions: Sickle Cell Disease | Phase 3 | Status: RECRUITING